$5.94
-0.07 (-1.16%)
Open$6.03
Previous Close$6.01
Day High$6.14
Day Low$5.93
52W High$33.20
52W Low$4.94
Volume—
Avg Volume1.14M
Market Cap244.25M
P/E Ratio—
EPS$-3.83
SectorBiotechnology
Analyst Ratings
Strong Buy
18 analysts
Price Target
+1,176.1% upside
Current
$5.94
$5.94
Target
$75.80
$75.80
$52.19
$75.80 avg
$91.23
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 20.46M | 78.02M | 75.69M |
| Net Income | -108,381,764 | -16,723,517 | -20,379,208 |
| Profit Margin | -529.8% | -21.4% | -26.9% |
| EBITDA | -125,398,511 | -28,105,243 | -27,281,553 |
| Free Cash Flow | — | -11,355,754 | -12,035,038 |
| Rev Growth | — | -7.7% | +21.3% |
| Debt/Equity | 0.00 | 0.34 | 0.31 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.34 | +1.08% | 81.4 | 513.86B |
| AMGN | Amgen Inc | $461.10 | +0.18% | 28.5 | 249.09B |
| GILD | Gilead Sciences Inc | $168.18 | +0.36% | — | 212.04B |
| VRTX | Vertex Pharmaceuticals Inc | $546.92 | +0.81% | 30.6 | 134.77B |
| REGN | Regeneron Pharmaceuticals | $908.12 | +0.58% | 19.5 | 84.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $157.53 | +0.56% | 28.8 | 23.28B |